| Bioactivity | DC-LC3in-D5 acts as an autophagy inhibitor by attenuating LC3B lipidation. DC-LC3in-D5 binds with LC3B. DC-LC3in-D5 disrupts the LC3B-LBP2 interaction with an IC50 of 200 nM. DC-LC3in-D5 may contribute to anti-HCV or combination treatments in cancer through inhibiting autophagy[1]. | ||||||||||||
| Invitro | DC-LC3in-D5 demonstrates high selectivity to LC3A/B in the proteome. DC-LC3in-D5 exhibits a potent covalent reactivity and selectivity to LC3A/B in HeLa cells[1].Treatment of HeLa cells with DC-LC3in-D5 (3-30 μM) results in disruption of LC3B lipidation, inhibition of autophagic vesicle formation, and accumulation of p62[1]. Western Blot Analysis[1] Cell Line: | ||||||||||||
| Name | DC-LC3in-D5 | ||||||||||||
| Formula | C19H22Cl2N2O3 | ||||||||||||
| Molar Mass | 397.30 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Shijie Fan, et al. Inhibition of Autophagy by a Small Molecule through Covalent Modification of the LC3 Protein. Angew Chem Int Ed Engl. 2021 Dec 6;60(50):26105-26114. |